Product Description
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies. (Sourced from: https://www.biolinerx.com/pipeline/bl-8040/overview)
Mechanisms of Action: CXCR4 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: Orphan Drug - Pancreatic Cancer *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioLineRx
Company Location: MODI-IN L3 7177871
Company CEO:
Additonal Commercial Interests: GenFleet Therapeutics (Australia)
Clinical Description

Countries in Clinic: China, Germany, Hungary, Israel, Italy, Japan, Korea, Spain, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Hematopoietic Stem Cell Transplant|Multiple Myeloma
Phase 2: Adenocarcinoma|Pancreatic Cancer
Phase 1: Anemia, Sickle Cell|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BL-8040.SCM.301 | P3 |
Unknown Status |
Multiple Myeloma|Hematopoietic Stem Cell Transplant |
2028-09-30 |
|
GLS-020-31 | P3 |
Not yet recruiting |
Multiple Myeloma |
2026-08-31 |
|
NCT06547112 | P1 |
Recruiting |
Multiple Myeloma |
2026-01-31 |
|
SCDSTEMM | P1 |
Recruiting |
Anemia, Sickle Cell |
2026-01-01 |